The report indicated the following data on cancer treatment abroad: four out of seven study participants had complete remission, and one had partial remission.
The company plans to move to the second phase, to continue research in 2016. Additional results are now expected for the first phase of research. The new drug is based on targeted immunotherapy and its use in treatment abroad. He received the status of a brand new drug from the US Federal Drug and Food Administration (FDA). This status allows you to speed up the approval process of the drug and, accordingly, the process of its entry into the market. It is planned that in the near future the drug will be used in well-known cancer centers in Israel.